Organogenesis Holdings Inc. (NASDAQ:ORGO) Shares Sold by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. reduced its position in Organogenesis Holdings Inc. (NASDAQ:ORGO) by 2.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 459,491 shares of the company’s stock after selling 11,749 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.37% of Organogenesis worth $1,470,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in ORGO. Rhumbline Advisers increased its stake in Organogenesis by 7.1% in the fourth quarter. Rhumbline Advisers now owns 115,266 shares of the company’s stock valued at $369,000 after purchasing an additional 7,621 shares during the last quarter. State Street Corp increased its stake in shares of Organogenesis by 0.6% during the 3rd quarter. State Street Corp now owns 1,459,767 shares of the company’s stock valued at $4,175,000 after acquiring an additional 9,090 shares during the last quarter. Captrust Financial Advisors purchased a new position in shares of Organogenesis during the 3rd quarter worth about $36,000. Intech Investment Management LLC acquired a new stake in shares of Organogenesis in the third quarter worth approximately $43,000. Finally, SG Americas Securities LLC boosted its position in shares of Organogenesis by 66.4% in the fourth quarter. SG Americas Securities LLC now owns 41,746 shares of the company’s stock worth $134,000 after acquiring an additional 16,660 shares during the last quarter. Hedge funds and other institutional investors own 49.57% of the company’s stock.

Analysts Set New Price Targets

Separately, Morgan Stanley increased their price target on shares of Organogenesis from $4.00 to $6.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 5th.

Insider Transactions at Organogenesis

In related news, Director Michael Joseph Driscoll sold 25,000 shares of the company’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total transaction of $127,500.00. Following the completion of the sale, the director now directly owns 166,879 shares of the company’s stock, valued at approximately $851,082.90. This represents a 13.03 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 36.90% of the company’s stock.

Organogenesis Stock Performance

Shares of NASDAQ:ORGO opened at $5.07 on Thursday. The business has a 50-day moving average of $3.97 and a two-hundred day moving average of $3.47. The firm has a market capitalization of $643.02 million, a PE ratio of -84.50 and a beta of 1.66. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74. Organogenesis Holdings Inc. has a 12 month low of $2.17 and a 12 month high of $6.71.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.